Myval THV matches SAPIEN and Evolut THVs in 30-day outcomes, supporting its role in severe aortic stenosis treatment.
Corporation (NASDAQ:NVNO), a medical device company with a market capitalization of $54.5 million, reported interim two-year follow-up data from its pivotal trial of the VenoValve, indicating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback